Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab

Maribeth A. Hohenstein, Samuel C. Augustine, Frank Rutar, Julie M. Vose

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Radioimmunotherapy with radiolabeled anti-CD20 antibodies is a promising new treatment approach for low-grade non-Hodgkin's lymphoma. However, the administration of radiolabeled antibodies presents some added complexity. At the University of Nebraska Medical Center (Omaha, NE), an institutional model has been developed that ensures the efficient and safe delivery of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA). An integrated, multidisciplinary treatment team is responsible for managing all aspects of treatment. Using this model, it is possible to administer tositumomab and iodine I 131 tositumomab safely and effectively in the outpatient setting. Patients can usually be released immediately after treatment. Guidelines and instructions for patient release have been developed and validated and are provided herein. These instructions ensure that radiation exposure of family members and caregivers who are exposed to the patient is maintained as low as reasonably achievable and well within regulatory limits.

Original languageEnglish
Pages (from-to)39-49
Number of pages11
JournalSeminars in Oncology
Volume30
Issue number2 SUPPL. 4
StatePublished - Apr 2003

Fingerprint

Non-Hodgkin's Lymphoma
Radioimmunotherapy
San Francisco
Therapeutics
Caregivers
Anti-Idiotypic Antibodies
Outpatients
iodine-131 anti-B1 antibody
Guidelines
Antibodies
Radiation Exposure

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab. / Hohenstein, Maribeth A.; Augustine, Samuel C.; Rutar, Frank; Vose, Julie M.

In: Seminars in Oncology, Vol. 30, No. 2 SUPPL. 4, 04.2003, p. 39-49.

Research output: Contribution to journalReview article

Hohenstein, Maribeth A. ; Augustine, Samuel C. ; Rutar, Frank ; Vose, Julie M. / Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab. In: Seminars in Oncology. 2003 ; Vol. 30, No. 2 SUPPL. 4. pp. 39-49.
@article{12203f944e2c40f9bcb3de0098203182,
title = "Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab",
abstract = "Radioimmunotherapy with radiolabeled anti-CD20 antibodies is a promising new treatment approach for low-grade non-Hodgkin's lymphoma. However, the administration of radiolabeled antibodies presents some added complexity. At the University of Nebraska Medical Center (Omaha, NE), an institutional model has been developed that ensures the efficient and safe delivery of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA). An integrated, multidisciplinary treatment team is responsible for managing all aspects of treatment. Using this model, it is possible to administer tositumomab and iodine I 131 tositumomab safely and effectively in the outpatient setting. Patients can usually be released immediately after treatment. Guidelines and instructions for patient release have been developed and validated and are provided herein. These instructions ensure that radiation exposure of family members and caregivers who are exposed to the patient is maintained as low as reasonably achievable and well within regulatory limits.",
author = "Hohenstein, {Maribeth A.} and Augustine, {Samuel C.} and Frank Rutar and Vose, {Julie M.}",
year = "2003",
month = "4",
language = "English",
volume = "30",
pages = "39--49",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 4",

}

TY - JOUR

T1 - Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab

AU - Hohenstein, Maribeth A.

AU - Augustine, Samuel C.

AU - Rutar, Frank

AU - Vose, Julie M.

PY - 2003/4

Y1 - 2003/4

N2 - Radioimmunotherapy with radiolabeled anti-CD20 antibodies is a promising new treatment approach for low-grade non-Hodgkin's lymphoma. However, the administration of radiolabeled antibodies presents some added complexity. At the University of Nebraska Medical Center (Omaha, NE), an institutional model has been developed that ensures the efficient and safe delivery of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA). An integrated, multidisciplinary treatment team is responsible for managing all aspects of treatment. Using this model, it is possible to administer tositumomab and iodine I 131 tositumomab safely and effectively in the outpatient setting. Patients can usually be released immediately after treatment. Guidelines and instructions for patient release have been developed and validated and are provided herein. These instructions ensure that radiation exposure of family members and caregivers who are exposed to the patient is maintained as low as reasonably achievable and well within regulatory limits.

AB - Radioimmunotherapy with radiolabeled anti-CD20 antibodies is a promising new treatment approach for low-grade non-Hodgkin's lymphoma. However, the administration of radiolabeled antibodies presents some added complexity. At the University of Nebraska Medical Center (Omaha, NE), an institutional model has been developed that ensures the efficient and safe delivery of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA). An integrated, multidisciplinary treatment team is responsible for managing all aspects of treatment. Using this model, it is possible to administer tositumomab and iodine I 131 tositumomab safely and effectively in the outpatient setting. Patients can usually be released immediately after treatment. Guidelines and instructions for patient release have been developed and validated and are provided herein. These instructions ensure that radiation exposure of family members and caregivers who are exposed to the patient is maintained as low as reasonably achievable and well within regulatory limits.

UR - http://www.scopus.com/inward/record.url?scp=0345532410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345532410&partnerID=8YFLogxK

M3 - Review article

VL - 30

SP - 39

EP - 49

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 4

ER -